器官移植2025，Vol.16Issue(5)：756-762,7.DOI:10.12464/j.issn.1674-7445.2025175
舒巴坦-度洛巴坦用于肺移植术后抗感染治疗
Sulbactam-durlobactam for anti-infection treatment after lung transplantation
摘要
Abstract
Objective To summarize the clinical experience of the first case of sulbactam-durlobactam treatment for extensively drug-resistant Acinetobacter baumannii infection after lung transplantation in China.Methods A retrospective analysis was conducted on a case of a patient with severe chronic obstructive pulmonary disease who received sulbactam-durlobactam treatment after lung transplantation.Results A 68-year-old male patient with a history of drug-resistant Acinetobacter baumannii infection before surgery,experienced worsening infection and impaired renal function after lung transplantation,with sputum culture showing extensively drug-resistant Acinetobacter baumannii.After receiving combination treatment with sulbactam-durlobactam and meropenem,the infection was controlled,and the function of the transplanted lung was restored.Conclusions Sulbactam-durlobactam has potential therapeutic value for extensively drug-resistant Acinetobacter baumannii infection after lung transplantation and provides a new strategy for clinical practice.关键词
舒巴坦-度洛巴坦/肺移植/感染/慢性阻塞性肺疾病/革兰阴性杆菌/广泛耐药鲍曼不动杆菌/美罗培南/重症监护室Key words
Sulbactam-durlobactam/Lung transplantation/Infection/Chronic obstructive pulmonary disease/Gram-negative bacilli/Extensively drug-resistant Acinetobacter baumannii/Meropenem/Intensive care unit分类
医药卫生引用本文复制引用
王璐琳,王晓华,张婕,周守宁,喻鹏玖,巨春蓉..舒巴坦-度洛巴坦用于肺移植术后抗感染治疗[J].器官移植,2025,16(5):756-762,7.基金项目
国家自然科学基金(82470103) （82470103）
广州市临床特色技术项目(2023C—TS10) （2023C—TS10）
广州医科大学科研能力提升计划重大临床研究项目(GMUCR2024-01007) （GMUCR2024-01007）
呼吸系统疾病国家重点实验室临床流行病学研究项目(SKLRD-L-202504) （SKLRD-L-202504）
中国医药教育协会(ZJWYH-2023-YIZHI-003) （ZJWYH-2023-YIZHI-003）
吴阶平医学基金会科研专项资助基金(320.6750.2025-01-1) （320.6750.2025-01-1）
